Giorgino Francesco, Battelino Tadej, Bergenstal Richard M, Forst Thomas, Green Jennifer B, Mathieu Chantal, Rodbard Helena W, Schnell Oliver, Wilmot Emma G
Section of Internal Medicine, Endocrinology, Andrology and Metabolic Diseases, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari Aldo Moro, Bari, Italy.
Department of Endocrinology, Diabetes and Metabolism, UCH-University Medical Center Ljubljana, Ljubljana, Slovenia.
J Diabetes Sci Technol. 2025 Mar;19(2):452-469. doi: 10.1177/19322968231204584. Epub 2023 Nov 8.
Ultra-rapid-acting insulin analogs (URAA) are a further development and refinement of rapid-acting insulin analogs. Because of their adapted formulation, URAA provide an even faster pharmacokinetics and thus an accelerated onset of insulin action than conventional rapid-acting insulin analogs, allowing for a more physiologic delivery of exogenously applied insulin. Clinical trials have confirmed the superiority of URAA in controlling postprandial glucose excursions, with a safety profile that is comparable to the rapid-acting insulins. Consequently, many individuals with diabetes mellitus may benefit from URAA in terms of prandial glycemic control. Unfortunately, there are only few available recommendations from authoritative sources for use of URAA in clinical practice. Therefore, this expert consensus report aims to define populations of people with diabetes mellitus for whom URAA may be beneficial and to provide health care professionals with concrete, practical recommendations on how best to use URAA in this context.
超速效胰岛素类似物（URAA）是速效胰岛素类似物的进一步发展和优化。由于其适应性配方，URAA的药代动力学更快，因此与传统速效胰岛素类似物相比，胰岛素作用起效更快，能够更生理性地输送外源性应用的胰岛素。临床试验已证实URAA在控制餐后血糖波动方面的优越性，其安全性与速效胰岛素相当。因此，许多糖尿病患者可能在餐时血糖控制方面从URAA中获益。不幸的是，权威来源关于URAA在临床实践中使用的可用建议很少。因此，本专家共识报告旨在确定可能从URAA中获益的糖尿病患者群体，并为医疗保健专业人员提供关于如何在这种情况下最佳使用URAA的具体实用建议。
